Effects of traditional Chinese patent medicine on essential hypertension: A systematic review

Medicine (United States)

Volumn 94, Issue 5, 2015, Pages e442-

  Xiong, Xingjiang ^a   Wang, Pengqian ^a   Zhang, Yuqing ^b   Li, Xiaoke ^c  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b MCMASTER UNIVERSITY   (Canada)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HERBACEOUS AGENT;

ABDOMINAL DISCOMFORT; ANKLE EDEMA; ARTICLE; CHINA; CHINESE HERB; CHINESE MEDICINE; CONSTIPATION; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; ESSENTIAL HYPERTENSION; HEADACHE; HEART PALPITATION; HOT FLUSH; HUMAN; META ANALYSIS; MORTALITY; NAUSEA; NONHUMAN; NOSE OBSTRUCTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; XEROSTOMIA; ADVERSE EFFECTS; BLOOD PRESSURE; DRUG EFFECTS; HYPERTENSION; PROCEDURES;

BLOOD PRESSURE; CHINA; DISEASE PROGRESSION; HUMANS; HYPERTENSION; MEDICINE, CHINESE TRADITIONAL; QUALITY OF LIFE;

EID: 84922852835     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000442     Document Type: Article

References (106)

1. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). J Am Med Assoc. 2014;311:507-520.
2. Lawes CM, Hoorn SV, Rodgers A. and for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-1518.
3. Staessen JA, Wang JG, Bianchi G, et al. Essential hypertension. Lancet. 2003;361:1629-1641.
4. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
5. Guo F, He D, Zhang W, et al. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol. 2012;60:599-606.
6. Brook RD, Appel LJ, Rubenfire M, et al. Beyond medications and diet: alternative approaches to lowering blood pressure. Hypertension. 2013;61:1360-1383.
7. Xiong XJ, Yang XC, Liu YM, et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertens Res. 2013;36:570-579.
8. Wang J, Xiong XJ. Control strategy on hypertension in Chinese medicine. Evid Based Complement Alternat Med. 2012;2012:e2848471-6.
9. Wang J, Xiong XJ. Evidence-based Chinese medicine for hypertension. Evid Based Complement Alternat Med. 2013;2013:e9783981-12.
10. Macklin EA, Wayne PM, Kalish LA, et al. Stop hypertension with the acupuncture research program (SHARP): results of a randomized, controlled clinical trial. Hypertension. 2006;46:838-845.
11. Flachskampf FA, Gallasch J, Gefeller O, et al. Randomized trial of acupuncture to lower blood pressure. Circulation. 2007;115:3121-3129.
12. Lee H, Kim SY, Park J, et al. Acupuncture for lowering blood pressure: systematic review and meta-analysis. Am J Hypertens. 2009;22:122-128.
13. Wang J, Xiong XJ. Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews. Evid Based Complement Alternat Med. 2012;2012:e6972371-10.
14. Xiong XJ, Yang XC, Liu W, et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine. Evid Based Complement Alternat Med. 2013;2013:e2752791-13.
15. National Pharmacopoeia Committee. Pharmacopoeia of People's Republic of China. Part 1. China Med Sci Press. 2010:1-1248.
16. Li J, Gao XM, Zhang BL, et al. Effect of yang xue qing nao granules on blood pressure and plasma levels of endothelin, calcitonin gene related peptide and NO in rats with renal hypertension. Tradit Chin Drug Res Clin Pharmaco. 2005;16:20-23.
17. Yu SY. The effect of niuhuang jiang ya pills on blood pressure and sympathetic activity. China J Chin Mater Medica. 2007;32:172-175.
18. Wu SX, Lin XS. Clinical effect of liu wei dihuang wan on the level of vWF in patients with hypertension. Fujian J Tradit Chin Med. 2000;31:5-6.
19. Zhao YQ, Liu W, Cai XY, et al. Effects of Song ling xue mai kang capsule for spontaneously hypertensive rats with hyperactivity of liver yang. Liaoning J Tradit Chin Med. 2012;39:1923-1925.
20. Higgins JPT, Green S. Cochrane Reviewers' Handbook 5.1.0 [updated March 2011.], Review Manager (RevMan) [Computer program.]. Version 5.1.0. Available from www.cochrane-handbook.org.
21. Niu ZH. Clinical research of song ling xue mai kang capsule on hypertension. Chengdu: Chengdu Univ Chin Med. 2008:1-46.
22. Shen M. Clinical observation of the combination of amlodipine and song ling xue mai kang capsule on elderly patients with hypertension. J Pract Med. 2012;28:1711-1712.
23. Shen M, Fang QM, Hu Y. Efficacy of losartan combined with song ling xue mai kang on patients with hypertension and metabolic syndrome. Chin Gen Pract. 2012;15:1414-1416.
24. Zhao GX. Clinical observation of the combination of losartan and song ling xue mai kang on patients with hypertension and metabolic syndrome. Guide China Med. 2012;10:482-483.
25. Yin BD. Clinical observation of the combination of losartan and song ling xue mai kang on 76 cases of patients with essential hypertension. Med Inform. 2011;24:4926-4927.
26. Li YD, Liu D, Dong CH. The effects of song ling xue mai kang capsule on heart rate variability in patients with primary hypertension. J Clin Electrocardiol. 2011;20:354-356.
27. Yu Q, Li X, Yang Y. Effect of song ling xue mai kang capsule on pulse wave velocity and endothelial function in hypertensive patients. W China J Pharm Sci. 2011;26:298-299.
28. Fu L, Mao ZX, Wang J, et al. Effects of song ling xue mai kang capsule on ambulatory blood pressure in treatment of essential hypertension: a single-blind randomized controlled trial. J Chin Integr Med. 2009;7:509-513.
29. Weng JL, Zheng Z. The clinical research of song ling xue mai kang ameliorating the compliance and endothelial function of artery in hypertensive patients. J Hunan Univ Chin Med. 2011;31:62-64.
30. Liu J. Effects of song ling xue mai kang capsule combined with benazepril on non-dipper hypertension. Med J Commun. 2007;21:648-649.
31. Chang XY. Effects of song ling xue mai kang capsule combined with nifedipine on essential hypertension. Chin J Integr Med Cardio-cerebrovasc Dis. 2012;10:619-620.
32. Zheng WW. Clinical observation on song ling xue mai kang combined with levamlodipine in treatment of female menopausal hypertension. China Pract Med. 2012;7:29-30.
33. Jiang WF, Wang LQ, Huo BL. Effect of song ling xue mai kang combined with levamlodipine for the treatment of female menopausal hypertension. China Med Eng. 2011;19:67-6870.
34. Wang FQ. Effect of song ling xue mai kang combined with levamlodipine on blood pressure variability in patients with essential hypertension. Jilin J Tradit Chin Med. 2011;31:149-150.
35. Weng JL, Zhang FW. Effect of song ling xue mai kang combined with losartan potassium on 58 patients of essential hypertension with liver yang hyperactivity syndrome. Med Inform. 2005;8:933.
36. Cui JJ, Liu W, Peng DL. Effect of song ling xue mai kang combined with valsartan on quality of life in hypertensive patients. Chin J Integr Med Cardio-cerebrovasc Dis. 2011;9:533-534.
37. Ge CY. Effect of song ling xue mai kang capsule combined with valsartan on essential hypertension. Chin J Integr Med Cardiocerebrovasc Dis. 2012;10:515-516.
38. Li H. Effect of valsartan combined with song ling xue mai kang capsule on essential hypertension. Chin J Integr Med Cardiocerebrovasc Dis. 2011;9:911-912.
39. He ZM, Liang YR. Disscussion on the effect of valsartan combined with song ling xue mai kang capsule on essential hypertension. Pract J Cardiac Cereb Pneumal Vasc Dis. 2006;14:968-969.
40. Li XY, Du YB, Chen WL. Effect of song ling xue mai kang capsule on blood pressure and left ventricular hypertrophy in elderly patients with hypertension. Yunnan J Tradit Chin Med Mater Medica. 2009;30:10-12.
41. Liu ZY, Li Q, Luo Y, et al. Effect of song ling xue mai kang capsule on left ventricular hypertrophy in hypertensive patients. J Pract Med. 2007;23:2599-2600.
42. Chen WQ, Chen FR. Effect of song ling xue mai kang capsule combined with captopril on quality of life in primary hypertension patients. Chin J Integr Tradit West Med. 2001;21:660-662.
43. Zhou P, Zhou J. Effect of song ling xue mai kang capsule on 34 cases of hypertension with coronary heart disease. J Commun Med. 2012;10:26-27.
44. Xu LR, Gao XW, Chen JX. Effect of song ling xue mai kang capsule on 34 cases of elderly patients with hypertension of liver yang hyperactivity syndrome. Fujian J Tradit Chin Med. 2010;41:45.
45. Liu AF, Yin JY, Meng X, et al. Effect of valsartan combined with yang xue qing nao granule on 60 cases of essential hypertension. Shandong Med J. 2009;49:65-66.
46. Chen WF, Zhan DM, Liu YH. Role of yang xue qing nao granule in rehabilitation of hypertensive patients. Chin J Integr Med Cardio-cerebrovasc Dis. 2006;4:746-747.
47. Ji RL, Han QH. Effect of yang xue qing nao granule on hypertensive patients and related symptoms. Chin J Integr Med Cardio-cerebrovasc Dis. 2011;9:263-265.
48. Li LY. Effect of yang xue qing nao granule combined with calcium channel blockers on hypertension. J Jiangxi Med Coll. 2006;46:188.
49. Li Y, Wan N. Effect of yang xue qing nao granule and indapamide on 40 cases of isolated systolic hypertension. Chin J Inform Tradit Chin Med. 2006;13:59-61.
50. Liang L. Application of yang xue qing nao granule on hypertension. Chin J Mod Drug Appl. 2011;5:87-88.
51. Fu Y, Xiao F. Effect of yang xue qing nao granule on 992 cases of hypertensive patients. Tianjin J Tradit Chin Med. 2011;28:188-190.
52. Qin Y, Wang M, Xu BP, et al. Effect of yang xue qing nao granule on 50 cases of hypertensive patients. Chin Tradit and Herb Drugs. 2003;34:1032-1033.
53. Yuan ZQ. Effect of yang xue qing nao granule on headache in hypertensive patients. Mod Med J China. 2006;8:95-96.
54. Shi CE. Effect of yang xue qing nao granule combined with felodipine on elderly patients with hypertension. China Health Mon. 2011;30:47-48.
55. Huang CY, Li YC, Liao ZM. Effect of liu wei di huang pill on urinary microalbumin in hypertensive patients. J Changchun Univ Tradit Chin Med. 2011;27:423-424.
56. Cai LH. Effect of liu wei di huang pill on ET and NO in elderly patients with hypertension. Arch Tradit Chin Med. 2004;22:1280-1281.
57. Zhang TD, Li CX. Renal protective effect of liu wei di huang pill in elderly hypertensive patients. World Sci Technol/Mod Tradit Chin Med Mater Medica. 2006;8:102-105.
58. Zhang YB. Effect of liu wei di huang pill onb2-microglobulin in hypertensive patients. Chongqing J Res Chin Drugs Herbs. 2006;2:28-29.
59. Ye Y, Huang FX, Wang Y, et al. Effect of liu wei di huang pill combined with amlodipine besylate tablets on female menopausal hypertension. J Emerg Tradit Chin Med. 2006;15:487-488.
60. Chen GQ, Lai WY, Chen K, et al. Clinical study on the therapy of elder essential hypertension using liu wei di huang pill and captopril. J Hainan Med Coll. 2008;14:357-359.
61. Wu SX, Lin XS. Clinical study of liu wei di huang pill on vWF in hypertensive patients. Fujian J Tradit Chin Med. 2000;31:5-6.
62. Zhou YL, Zhou ZW, Tang MX. Clinical study of combination of liu wei di huang pills and basintom for the treatment of essential hypertension. Guid J Tradit Chin Med Pharm. 2003;9:15-16.
63. Hu LB, Ma HY, Yang ZF, et al. Clinical immunology of essential hypertension belonged to the types of yang hyperactivity and yin deficiency treated by combining liu wei rehmannia pill with nifedipine. J Xinxiang Med Coll. 1994;11:279-282.
64. Zhan HB. Effect of liu wei di huang pill combined with captopril on essential hypertension in rural areas. Guide China Med. 2013;11:587-588.
65. Zhang N, Liu L, Jin J. Clinical study of integrative medicine for the treatment of essential hypertension. J Inform Tradit Chin Med. 2004;21:29-30.
66. Chen J, Zhu LM. Effect of quan tianma capsule combined with nifedipine on rheology and endpoint events in hypertensive patients. Guangmin Tradit Chin Med. 2011;26:2090-2091.
67. Liu Y, Liu XJ, Liao YG, et al. Clinical observation on the treatment of essential hypertension by full tianma capsule and valsartan. Prog Mod Biomed. 2012;32:6331-6334.
68. Li XG, Liao XQ, Lai Z. Clinical observation on the treatment of 36 cases of hypertension headache by quan tianma capsule. Med J Chin People's Health. 2007;19:146-147.
69. Qiu XF, Zhang L. Lacidipine and irbesartan combined with xin ke shu tablet in treatment of systolic hypertension. Mod Chin Doct. 2012;50:71-73.
70. Ying XX. Clinical effect of xin ke shu combined with irbesartan on myocardial ischemia in left ventricular hypertrophy. Zhejiang J Integr Tradit West Med. 2012;22:101-102.
71. Qiu XF, Zhang L. Therapeutic effects of xin ke shu tablet with irbesartan and amlodipine for treatment of left ventricular hypertrophy and myocardial ischemia in moderate and severe hypertension. Chin J Integr Med Cardio-cerebrovasc Dis. 2010;8:1281-1283.
72. Li M, Xu Z, Hou Y. Effect of xin ke shu tablet on the endothelial function of patients with essential hypertension. Chin Arch Tradit Chin Med. 2008;26:671-672.
73. Zhu M, Zang YF, Ma CH. Sixty-two cases of essential hypertension with yin deficiency and yang excess treated by supplementing qing nao jiang ya tablets. Chin J Exp Tradit Med Formulae. 2013;19:292-294.
74. Suo ZR, Guan ZX. Effect of qing nao jiang ya tablet combined with amlodipine on elderly patients with isolated systolic hypertension. Chin J Integr Med Cardio-cerebrovasc Dis. 2009;7:1246-1247.
75. Yang YL, Tang YQ, Yang JR. Effect of qing nao jiang ya tablet on 60 cases of elderly patients with isolated systolic hypertension. Shanxi J Tradit Chin Med. 2010;31:661-662.
76. Zhu ZD, Li CL, Wang QG. Effect of tianma gouteng granule on quality of life in hypertensive patients. Fujian J Tradit Chin Med. 2010;41:6-7.
77. Zhou JR. Clinical observation on tianma gouteng granules combined with western medicine for treatment of senile hypertension. Chin J Exp Tradit Med Formulae. 2013;19:327-330.
78. Jia QM, Liu SY. Clinical observation on tianma gouteng granules combined with levamlodipine besylate tablets on 34 cases of hypertensive patients. Chin Commun Doct. 2004;6:52-54.
79. Dong LH, Han GJ. Clinical observation on qiang li tianma duzhong capsule combined with valsartan on mild to moderate essential hypertension. Chin Tradit Pat Med. 2009;31:1164-1166.
80. Fu XD, Wang YY, Chen Y, et al. Clinical observation on qiang li tianma duzhong capsule on elderly patients with hypertension. Chin Tradit Pat Med. 2006;28:1455-1457.
81. Wang XY. Clinical observation on qiang li tianma duzhong capsule on essential hypertension with liver yang hyperactivity syndrome. Heilongjiang J Tradit Chin Med. 2004;40:5.
82. Yang S, Chen YP. Clinical observation on qi ju dihuang pill combined with small dose of metoprolol on hypertension. Clin Focus. 2005;20:1005-1006.
83. Liang T. Clinical study of qi ju dihuang pill on hypertension with liver and kidney yin deficiency. J Med Forum. 2013;34:122-123.
84. Wang J, Miao HW. Effect of Niuhuang jiang ya pill on endothelial function in patients with hypertension. Shijiazhuang: Hebei Med Univ. 2011;36:1-34.
85. Cai BH. Clinical observation of niuhuang jiang ya pill combined with captopril on essential hypertension. Tianjin Pharm. 2009;21:36-37.
86. Yuan ZD. Clinical observation of niuhuang jiang ya pill combined with amlodipine on hypertension. J Hebei United Univ (Health Sci). 2012;14:514-515.
87. Sheng DP. Clinical effect of zhen ju jiang ya tablet combined with irbesartan on hypertension. Strait Pharm J. 2013;25:141-142.
88. Liu KQ. Clinical observation of nifedipine controlled-release tablets combined with qiang li ding xuan tablets on hypertension. Drugs Clin. 2013;28:358-360.
89. Ou WE. Clinical observation of tianma shouwu tablets in treatment of 40 cases of hypertension. Hunan J Tradit Chin Med. 2002;18:58-59.
90. Zhao YY. Study of efficacies of nifedipine (I) and qing gan jiang ya capsule joint therapy on elderly hypertensive patients. Pract J Cardiac Cereb Pneumal Vasc Dis. 2012;20:645-646.
91. Ge H, Xie JX, Wang SY, et al. The blood pressure lowering effect of qing xuan: compared with nitrendipine. Chin Pharm J. 2000;35:202-203.
92. Liang DS, Yuan D. Clinical effect of tian shu capsule and levamlodipine besylate tablets on patients with hypertension of blood stasis. Pharm Today. 2011;21:452-454.
93. Yu YG, Pan ZM, Ma K. Effect of cornu saigae tataricae capsule on 30 cases of left ventricular hypertrophy in hypertensive patients. Zhejiang J Integr Tradit West Med. 2005;15:762-763.
94. Croog SH, Levine S, Testa MA, et al. The effect of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314:1657-1659.
95. Ware JE. SF-36 Health Survey. Manual and Interpretation Guide. Bostion. MA: The Health Institute, New England Medical Center 1993; 465-470.
96. Xiong XJ, Liu W, Yang XC, et al. Ginkgo biloba extract for essential hypertension: a systemic review. Phytomedicine. 2014;21:1131-1136.
97. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol. 2010;55:515-525.
98. Vogel JH, Bolling SF, Costello RB, et al. Integrating complementary medicine into cardiovascular medicine. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine). J Am Coll Cardiol. 2005;46:184-221.
99. Liu X, Wu WY, Jiang BH, et al. Pharmacological tools for the development of traditional Chinese medicine. Trends Pharmacol Sci. 2013;34:620-628.
100. Wang J, Xiong XJ. Current situation and perspectives of clinical study in integrative medicine in China. Evid Based Complement Alternat Med. 2012;2012:e2685421-11.
101. Bell IR, Caspi O, Schwartz GE, et al. Integrative medicine and systemic outcomes research: issues in the emergence of a new model for primary health care. Arch Intern Med. 2002;162:133-140.
102. Xiong XJ, Borrelli F, Ferreira AS, et al. Herbal medicines for cardiovascular diseases. Evid Based Complement Alternat Med. 2014;2014:e8097411-2.
103. Lewington S, Clarke R, Qizilbash N, et al., prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
104. Kinsel JF, Straus SE. Complementary and alternative therapeutics: rigorous research is needed to support claims. Annu Rev Pharmacol Toxicol. 2003;43:463-484.
105. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2012;152:726-732.
106. Gagnier JJ, Boon H, Rochon P, et al., CONSORT Group. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med. 2006;144:364-367.